GHRP-2 (Pralmorelin) is a synthetic hexapeptide that functions as a potent agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a). In cellular assays, this compound demonstrates a high binding affinity, initiating a robust intracellular signalling cascade. Upon receptor activation, it triggers the phospholipase C pathway, leading to an accumulation of inositol triphosphate (IP3) and a subsequent release of intracellular calcium ions. Researchers investigating ghrelin mimetics often utilise GHRP-2 to observe these calcium-dependent cellular responses in vitro. As a premium research chemical, UK laboratories utilise this peptide to study somatotropic pathways and cellular metabolism. During experimental preparation, strict adherence to established reconstitution protocols is essential to maintain the structural integrity of the peptide. Advanced peptide synthesis techniques ensure that the molecular stability of GHRP-2 remains optimal across various laboratory environments. For further structural details, researchers can consult its PubChem entry.
Public search data clusters around GHRP-2 (Pralmorelin) regarding its role as a growth hormone secretagogue. Published studies discussed under this heading examine the peptide in isolated cell cultures and receptor binding models. Amino Peptides supplies this compound only as a lyophilised laboratory reagent. Strictly for laboratory research.
- Agonistic binding to the growth hormone secretagogue receptor 1a (GHSR-1a), a G protein-coupled receptor predominantly expressed in pituitary and hypothalamic cell models.
- Interaction with CD36 scavenger receptors in isolated macrophage populations, modulating lipid accumulation and cellular inflammatory cascades.
- Binding affinity studies demonstrate competitive displacement of endogenous ghrelin in cell-free membrane preparations.
- Activation of the phospholipase C (PLC) signalling pathway, leading to intracellular calcium mobilization and subsequent exocytosis of secretory vesicles in somatotroph cell models.
- Upregulation of cyclic AMP (cAMP) and protein kinase A (PKA) transcription networks, enhancing gene expression profiles associated with cellular growth factors.
- Attenuation of pro-inflammatory cytokine secretion (TNF-alpha and IL-6) via inhibition of NF-kappaB nuclear translocation in cultured immune cells.
Technical Specifications
Variant Breakdown
- 5mg Vial: Provides a standard quantity for preliminary cellular assays, receptor binding studies, and short-term in-vitro investigations.
- 10mg Vial: Optimised for high-throughput screening, longitudinal stability testing, and extensive laboratory characterisation requiring larger peptide reserves.
Quality Assurance
- HPLC Verification: High-performance liquid chromatography is utilised to confirm a purity level exceeding 99%, ensuring the absence of synthesis truncations.
- Mass Spectrometry: Molecular weight and structural identity are rigorously validated using advanced mass spectrometry techniques.
- Lyophilisation Process: The peptide is supplied as a lyophilised solid, processed under strict conditions to preserve long-term structural integrity.
- Endotoxin Testing: Each batch undergoes stringent endotoxin analysis to guarantee suitability for sensitive in-vitro cellular environments.
Research Mechanism
- Receptor Binding: GHRP-2 acts as a selective agonist for the GHSR-1a receptor on the surface of target cells, initiating specific conformational changes.
- Signal Transduction: Activation of the receptor stimulates the phospholipase C (PLC) pathway, cleaving PIP2 into diacylglycerol (DAG) and inositol triphosphate (IP3).
- Calcium Mobilisation: The generation of IP3 triggers the release of calcium ions from the endoplasmic reticulum, rapidly increasing intracellular calcium concentrations.
- Kinase Activation: Elevated calcium and DAG levels subsequently activate protein kinase C (PKC), which phosphorylates downstream targets involved in cellular metabolism.
- Gene Expression: The resulting kinase cascades modulate transcription factors, providing a measurable in-vitro model for studying somatotropic cellular responses.
Reconstitution & Storage Data
| Vial Strength | Solvent Added | Resulting Concentration |
| 5mg | 1 mL Bacteriostatic Reconstitution Solution | 5.00 mg/mL |
| 5mg | 2 mL Bacteriostatic Reconstitution Solution | 2.50 mg/mL |
| 10mg | 1 mL Bacteriostatic Reconstitution Solution | 10.00 mg/mL |
| 10mg | 2 mL Bacteriostatic Reconstitution Solution | 5.00 mg/mL |
- Lyophilised (Powder): Store in a standard refrigerator (2-8°C) for up to 3 months. For long-term preservation, freeze at -20°C.
- Reconstituted (Liquid): Store at 2-8°C (Refrigerated).
Scientific References
Journal of Endocrinology: "In vitro characterisation of GHRP-2 binding to the ghrelin receptor" View Study
Cellular Signalling: "Signal transduction pathways activated by growth hormone secretagogues in pituitary cells" View Study
Peptides: "Structural determinants of GHRP-2 for GHSR-1a activation" View Study
Molecular and Cellular Endocrinology: "Calcium mobilisation by pralmorelin in cultured somatotrophs" View Study
International Journal of Pharmaceutics: "Stability and degradation kinetics of hexapeptide GH secretagogues in vitro" View Study
